For instance, the most common treatment emergent adverse events seen in the PCSK9 inhibitor treated CKD patients from ODYSSEY clinical trials were nasopharyngitis, urinary tract infection, and upper respiratory infection. This evidence concerns the gene PCSK9 and urinary tract infection.